Emulsomes Meet S-layer Proteins: An Emerging Targeted Drug Delivery System

被引:48
作者
Ucisik, Mehmet H. [1 ]
Sleytr, Uwe B. [2 ]
Schuster, Bernhard [3 ]
机构
[1] Istanbul Medipol Univ, Sch Engn & Nat Sci, Dept Biomed Engn, TR-34810 Istanbul, Turkey
[2] Univ Nat Resources & Life Sci BOKU Vienna, Inst Biophys, Dept Nanobiotechnol, A-1190 Vienna, Austria
[3] Univ Nat Resources & Life Sci BOKU Vienna, Inst Synthet Bioarchitectures, Dept Nanobiotechnol, A-1190 Vienna, Austria
基金
奥地利科学基金会;
关键词
Drug delivery system; emulsome; lipid nanoparticles; nanomedicine; S-layer proteins; SOLID LIPID NANOPARTICLES; B BEARING EMULSOMES; AMPHOTERICIN-B; FUSION PROTEINS; BODY DISTRIBUTION; COATED LIPOSOMES; ANTIVIRAL AGENT; AZIDOTHYMIDINE; FORMULATIONS; CONSTRUCTION;
D O I
10.2174/138920101604150218112656
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Here, the use of emulsomes as a drug delivery system is reviewed and compared with other similar lipidic nanoformulations. In particular, we look at surface modification of emulsomes using S-layer proteins, which are self-assembling proteins that cover the surface of many prokaryotic organisms. It has been shown that covering emulsomes with a crystalline S-layer lattice can protect cells from oxidative stress and membrane damage. In the future, the capability to recrystallize S-layer fusion proteins on lipidic nanoformulations may allow the presentation of binding functions or homing protein domains to achieve highly specific targeted delivery of drug-loaded emulsomes. Besides the discussion on several designs and advantages of composite emulsomes, the success of emulsomes for the delivery of drugs to fight against viral and fungal infections, dermal therapy, cancer, and autoimmunity is summarized. Further research might lead to smart, biocompatible emulsomes, which are able to protect and reduce the side effects caused by the drug, but at the same time are equipped with specific targeting molecules to find the desired site of action.
引用
收藏
页码:392 / 405
页数:14
相关论文
共 118 条
[1]  
Aggarwal BB, 2007, ADV EXP MED BIOL, V595, P1
[2]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[3]  
Amselem A.S., 1994, EMULSOMES NOVEL DRUG, P1369
[4]  
Amselem S, 1997, US Patent, Patent No. 5662932
[5]   Curcumin and cancer: An "old-age" disease with an "age-old" solution [J].
Anand, Preetha ;
Sundaram, Chitra ;
Jhurani, Sonia ;
Kunnumakkara, Ajaikumar B. ;
Aggarwal, Bharat B. .
CANCER LETTERS, 2008, 267 (01) :133-164
[6]   Bioavailability of curcumin: Problems and promises [J].
Anand, Preetha ;
Kunnumakkara, Ajaikumar B. ;
Newman, Robert A. ;
Aggarwal, Bharat B. .
MOLECULAR PHARMACEUTICS, 2007, 4 (06) :807-818
[7]  
[Anonymous], HDB NONMEDICAL APPL
[8]   A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations [J].
Barrett, JP ;
Vardulaki, KA ;
Conlon, C ;
Cooke, J ;
Daza-Ramirez, P ;
Evans, EGV ;
Hawkey, PM ;
Herbrecht, R ;
Marks, DI ;
Moraleda, JM ;
Park, GR ;
Senn, SJ ;
Viscoli, C .
CLINICAL THERAPEUTICS, 2003, 25 (05) :1295-1320
[9]  
Bisht Savita, 2009, Curr Drug Discov Technol, V6, P192
[10]  
BJORCK L, 1984, J IMMUNOL, V133, P969